Esophageal Cancer Clinical Trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
Must have disease progression after treatment with available therapies that are known to confer clinical benefit or must be intolerant to or ineligible for standard treatment.
Histologically confirmed advanced solid tumors (protocol-defined select solid tumors) with measurable lesions per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) that are considered nonamenable to surgery or other curative treatments or procedures.
Eastern Cooperative Oncology Group performance status score of 0 or 1.
Life expectancy > 12 weeks.
Willingness to avoid pregnancy or fathering children.
Laboratory values outside the Protocol-defined ranges.
Clinically significant cardiac disease.
History or presence of an electrocardiogram that, in the investigator's opinion, is clinically meaningful.
Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed (eg, evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain or CNS metastases).
Known additional malignancy that is progressing or requires active treatment.
Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy (including prior IO) and/or complications from prior surgical intervention before starting study treatment.
Prior receipt of an anti-immunotherapy-drugs-are-boosting-survival/" >PD-L1 therapy.
Treatment with anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
A 28-day washout for systemic antibiotics is required.
Probiotic usage while on study and during screening is prohibited.
Active infection requiring systemic therapy.
Known history of Human Immunodeficiency Virus (HIV)
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 30 Locations for this study
Boston Massachusetts, 02215, United States
Detroit Michigan, 48202, United States
Pittsburgh Pennsylvania, 15232, United States
Houston Texas, 77030, United States
Seattle Washington, 98195, United States
Camperdown New South Wales, 02050, Australia
Heidelberg Victoria, 03084, Australia
Melbourne Victoria, 03004, Australia
Nedlands Western Australia, 06009, Australia
Brussels , 01200, Belgium
Brussels , B-107, Belgium
Edegem , 02650, Belgium
Ghent , 09000, Belgium
Leuven , 03000, Belgium
Plovdiv , 04004, Bulgaria
Ruse , 07002, Bulgaria
Varna , , Bulgaria
Angers , 49000, France
Bordeaux , 33000, France
Marseille Cedex 5 , 13385, France
Rennes , 35042, France
Chiba , 277-8, Japan
Tokyo , 104-0, Japan
Dnipro , 49102, Ukraine
Kharkiv , 61166, Ukraine
Kherson , 73000, Ukraine
Kryvyi Rih , 50048, Ukraine
Lutsk , 43018, Ukraine
Sumy , 40022, Ukraine
Uzhgorod , 88000, Ukraine
Vyshhorod , 07352, Ukraine
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.